RecruitingPhase 4ACTRN12621001093875

The Topical Trial: topical sevoflurane applied to chronic non-healing ulcer wounds for up to 30 days

A feasibility trial to evaluate the efficacy and safety of topical sevoflurane applied to chronic non-healing ulcer wounds to determine its effect on pain control and wound healing over 30 days


Sponsor

Anaesthetic Research Department, Waikato Hospital

Enrollment

30 participants

Start Date

Mar 29, 2022

Study Type

Interventional

Conditions

Summary

The purpose of this study is to evaluate whether topical sevoflurane provides significant pain relief and no major side effects in managing chronic non-healing ulcers. Chronic ulcer wounds come from a variety of causes. Often they are a sign of advanced progression of chronic diseases such as peripheral vascular disease, diabetes and renal failure. Some ulcers are not amenable to a surgical intervention. Severe pain limits noninvasive treatment options including making it difficult to adequately debride any eschar (dead tissue) or unhealthy excess granulation tissue from the ulcer at the time of dressing changes, thus increasing the chance that the ulcer will become grossly infected, and reducing the likelihood that the ulcer will heal. Ulcers can remain unhealed for many months, which may lead to systemic infection or infection of deeper tissue (muscle or bone), worsening local tissue ischaemia and enlargement of the ulcer, and transition to a malignant process. Non-malignant ulcers are typically painful, sometimes foul smelling, and often require frequent dressing changes. These features highlight why a chronic ulcer may have a profound negative impact on a patient’s quality of life The available case reports indicate that topical sevoflurane is a promising, cost effective and safe treatment, however these are small case reports and further research is needed to show efficacy and safety across wider patient populations and to define the mechanism of action of topical sevoflurane in the setting of chronic painful ulcer management. Currently patients with ulcers with no surgical treatment option face painful non-invasive interventions and use of strong analgesics, including opioid medications. Opioids are typically only modestly effective at relieving ulcer pain and cause a range of significant adverse side effects. If proven, this treatment option will; make treatment of ulcers less painful for patients, reduce the negative impact of ulcers on a patients’ quality of life, decrease opioid use and the related adverse effects, and may increase the proportion of patients that achieve healing of their ulcers.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

Chronic ulcers — wounds that have not healed after three or more months — are often extremely painful and significantly reduce quality of life. They are common in people with conditions like diabetes, peripheral vascular disease, or kidney failure. Current pain relief options, including opioid medications, are often only partially effective and come with significant side effects. This study is testing whether applying a liquid anaesthetic agent called sevoflurane directly to the wound — rather than inhaling it as in general anaesthesia — can provide effective pain relief during wound dressings without causing harm. Small case reports have been promising, but larger studies are needed. You may be eligible if you are 18 or older, have a chronic ulcer (excluding wounds on the face or head) that has been present for more than three months, and the wound is painful. You are not eligible if your ulcer requires surgery, if you have a malignant (cancerous) ulcer, if you have a personal or family history of malignant hyperthermia, or if you have a known allergy to sevoflurane.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Direct topical irrigation of liquid sevoflurane to chronic painful non-healing ulcer beds. Sevoflurane comes in liquid form 100% solution The dose will be 1ml per square centermeter of ulcer wound.

Direct topical irrigation of liquid sevoflurane to chronic painful non-healing ulcer beds. Sevoflurane comes in liquid form 100% solution The dose will be 1ml per square centermeter of ulcer wound. A maximum of 1 application per day- or as often as a patient requires a dressing change- ie once every 2 or 3 days- up to 30 days in total or until dressing and wound care treatment is completed- whichever comes first. Mode of delivery is via syringe- irrigated gently- prior to wound cleaning and redressing. Application of medication should take 1 min or less. The application of sevoflurane will be the responsibility of the research staff and the wound care will be the responsibility of the nursing wound care team in the hospital setting or the primary care nurses in the community. This will involve 30 patients. Adherance to the protocol will remain with the research staff performing the intervention.


Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12621001093875